Gracell Biotechnologies

About:

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

Website: https://www.gracellbio.com

Top Investors: Wellington Management, RA Capital Management, OrbiMed, Janus Henderson Investors, Vivo Capital

Description:

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

Total Funding Amount:

$285M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Suzhou, Jiangsu, China

Founded Date:

2017-01-01

Founders:

Wei William Cao

Number of Employees:

251-500

Last Funding Date:

2023-08-07

IPO Status:

Public

Industries:

© 2025 bioDAO.ai